Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.91Last Year’s EPS
-1.56Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 142.89%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
Phathom Pharmaceuticals is experiencing solid prescription growth and is making strides towards profitability through cost management. However, challenges such as stock price constraints, leadership transitions, and strategic promotional cutbacks underscore the need for careful navigation in the coming quarters.Company Guidance
During the Phathom Pharmaceuticals First Quarter 2025 earnings call, CEO Steve Basta provided guidance emphasizing the company's focus on growing VOQUEZNA's sales and achieving profitability by 2026. The company has set a target to reduce its operating expenses to less than $55 million per quarter by Q4 2025, excluding interest, stock compensation, and certain accruals. This cost management strategy is intended to enable Phathom to reach profitable operations without requiring additional financing. The call also highlighted a successful start for VOQUEZNA, with an annualized run-rate of $120 million in net revenues within the first 18 months of launch. Phathom reported net revenues of $28.5 million for Q1 2025 and ended the quarter with $212 million in cash. The company plans to maintain its sales force strength while implementing cost-saving measures, such as reducing direct-to-consumer broadcast spending and pausing certain R&D activities. The company remains focused on managing costs and driving revenue growth to build a sustainable business.VOQUEZNA Revenue Milestone
Phathom Pharmaceuticals achieved an annualized run-rate of $120 million in net revenues for VOQUEZNA within the first 18 months of launch.
Prescription Growth
VOQUEZNA prescriptions exceeded 390,000 from launch through April 18, showing a 30% growth over the last 8 weeks and an 8% increase in the first quarter over the fourth quarter.
Commercial Coverage
VOQUEZNA has over 120 million lives covered, representing more than 80% of the total commercially insured market in the U.S.
Cost Management Initiatives
Phathom plans to reduce operating expenses to less than $55 million per quarter by Q4 2025, aiming for profitability in 2026 without additional financing.
PHAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $4.29 | $3.36 | -21.68% |
Mar 06, 2025 | $6.08 | $5.90 | -2.96% |
Nov 07, 2024 | $18.00 | $18.50 | +2.78% |
Aug 08, 2024 | $10.81 | $11.75 | +8.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Phathom Pharmaceuticals (PHAT) report earnings?
Phathom Pharmaceuticals (PHAT) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Phathom Pharmaceuticals (PHAT) earnings time?
Phathom Pharmaceuticals (PHAT) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAT EPS forecast?
PHAT EPS forecast for the fiscal quarter 2025 (Q2) is -0.91.